tiprankstipranks
Seres Therapeutics (MCRB)
NASDAQ:MCRB

Seres Therapeutics Stock Price & Analysis

632 Followers

MCRB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.50 - $11.69
Previous Close$6.19
Volume781.90K
Average Volume (3M)1.12M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$195.79M
Total Debt (Recent Filing)$33.30M
P/E Ratio-5.4
Beta-0.66
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.14
Shares Outstanding124,071,555
R-Squared0.03
Standard Deviation0.82
10 Day Avg. Volume991,513
30 Day Avg. Volume1,116,972
P/B Ratio34.55
P/S Ratio77.34
P/CF Ratio55.50
P/FCF Ratio-4.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside136.21% Upside
Rating ConsensusStrong Buy
Alpha0.07
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MCRB FAQ

What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $2.50 and its highest was $11.69 in the past 12 months.
    What is Seres Therapeutics’s market cap?
    Currently, no data Available
    When is Seres Therapeutics’s upcoming earnings report date?
    Seres Therapeutics’s upcoming earnings report date is Nov 09, 2022 which is in 35 days.
      How were Seres Therapeutics’s earnings last quarter?
      Seres Therapeutics released its earnings results on Aug 03, 2022. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.596 by -$0.104.
        Is Seres Therapeutics overvalued?
        According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Seres Therapeutics pay dividends?
          Seres Therapeutics does not currently pay dividends.
          What is Seres Therapeutics’s EPS estimate?
          Seres Therapeutics’s EPS estimate is -$0.47.
            How many shares outstanding does Seres Therapeutics have?
            Seres Therapeutics has 124,071,556 shares outstanding.
              What happened to Seres Therapeutics’s price movement after its last earnings report?
              Seres Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.596. Following the earnings report the stock price went up 8.537%.
                Which hedge fund is a major shareholder of Seres Therapeutics?
                Among the largest hedge funds holding Seres Therapeutics’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics’s shares valued at 49M.

                  ---

                  Seres Therapeutics Stock Analysis

                  Smart ScoreOutperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  8
                  The Seres Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Seres Therapeutics

                  Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis